Description: Molecular Partners AG operates as a clinical-stage biopharmaceutical company. It is developing Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of wet age-related macular degeneration, as well as for diabetic macular edema; and MP0250 that binds and inhibit vascular endothelial growth factor and hepatocyte growth factor pathways, which restores clinical sensitivity to various standard-of-care therapies in multiple myeloma. The company is also developing MP0274 that is in Phase I clinical trials for HER2-positive solid tumors; MP0310, which is in Phase I clinical trials for immuno-oncology; MPO317, a tumor-localized immune agonist that activates immune cells in the tumor; and Peptide-MHC, a tumor-localized immune-cell agonist to attack tumors. It has strategic partnerships with Allergan, Inc. and Amgen SA. Molecular Partners AG was founded in 2004 and is headquartered in Schlieren, Switzerland.
Home Page: www.molecularpartners.com
Wagistrasse 14
Schlieren,
8952
Switzerland
Phone:
41 44 755 77 00
Officers
| Name | Title |
|---|---|
| Dr. Patrick Amstutz Ph.D. | Co-Founder, CEO, Member of Management Board & Director |
| Dr. Michael Tobias Stumpp Ph.D. | Co-Founder, Executive VP of Projects & Member of Management Board |
| Mr. Robert Hendriks | Senior VP of Finance |
| Mr. Alexander Zurcher | COO & Member of Management Board |
| Ms. Renate Gloggner | Executive VP of People & Community and Member of Management Board |
| Mr. Daniel Steiner Ph.D. | Senior Vice President of Research & Technology |
| Mr. Seth D. Lewis | Senior Vice President of Investor Relations, Communications & Strategy |
| Mr. Michael Pitzner | General Counsel, Compliance Officer, Senior VP Legal & Business Development |
| Dr. Pamela A. Trail Ph.D. | Strategic Consultant |
| Ms. Anne Goubier D.V.M., Ph.D. | Senior Vice President of Research & Early Development |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 153.8462 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.0782 |
| Price-to-Sales TTM: | 34.0226 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 167 |